Barclays PLC decreased its holdings in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 12.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 130,172 shares of the biotechnology company’s stock after selling 18,601 shares during the quarter. Barclays PLC owned about 0.15% of Arrowhead Pharmaceuticals worth $938,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of ARWR. Quantitative Systematic Strategies LLC bought a new position in shares of Arrowhead Pharmaceuticals in the first quarter worth $100,000. Vanguard Capital Wealth Advisors bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $119,000. Macquarie Group Ltd. bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $123,000. Jane Street Group LLC bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $130,000. Finally, Trexquant Investment LP bought a new position in shares of Arrowhead Pharmaceuticals in the first quarter worth $139,000. 46.31% of the stock is currently owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals opened at $13.47 on Tuesday, according to MarketBeat.com. The firm has a market capitalization of $1.16 billion, a P/E ratio of -28.66 and a beta of 2.57. The company has a current ratio of 10.16, a quick ratio of 10.16 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals Inc has a 52 week low of $1.48 and a 52 week high of $14.24.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.01. The business had revenue of $0.65 million for the quarter, compared to analysts’ expectations of $4.04 million. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. sell-side analysts anticipate that Arrowhead Pharmaceuticals Inc will post -0.74 earnings per share for the current fiscal year.
In related news, CFO Kenneth Allen Myszkowski sold 20,000 shares of the stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $14.01, for a total value of $280,200.00. Following the transaction, the chief financial officer now owns 330,815 shares of the company’s stock, valued at $4,634,718.15. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Douglas B. Given sold 25,000 shares of the stock in a transaction on Tuesday, April 24th. The shares were sold at an average price of $6.63, for a total value of $165,750.00. The disclosure for this sale can be found here. In the last three months, insiders sold 59,000 shares of company stock worth $599,950. 4.60% of the stock is owned by insiders.
Several research firms have recently weighed in on ARWR. S&P Equity Research decreased their price target on shares of Arrowhead Pharmaceuticals from $13.76 to $11.68 in a report on Monday, June 18th. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $13.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, June 18th. Piper Jaffray Companies upped their price target on shares of Arrowhead Pharmaceuticals to $11.00 and gave the stock an “overweight” rating in a report on Tuesday, May 8th. Finally, ValuEngine raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Arrowhead Pharmaceuticals presently has an average rating of “Buy” and an average target price of $9.45.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.